KRAScendo 1: the first head-to-head comparison in KRAS G12C-targeted therapy, presented at ESMO and published in NEJM.

Back to meeting Original

Back to meeting

Mustafa Özdoğan, MD· @ozdogan_md · X·2026-10-26 00:01· 1 day agoScore70

Body

KRAScendo 1: the first head-to-head comparison in KRAS G12C-targeted therapy, presented at ESMO and published in NEJM.

Does this change second-line standard of care?

#ESMO26 #Oncology #LungCancer

107 views · 1 like · 1 repost · 0 replies

Conference abstracts

2551TIPNCT07541170 NCT07541170 NCT07541170matched by NSCLC, early stage

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

Source: Mustafa Özdoğan, MD · x.com